TGFB3 Antibody - #AF0261

(4)   (3)  
Product: TGFB3 Antibody
Catalog: AF0261
Description: Rabbit polyclonal antibody to TGFB3
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 13kDa; 47kD(Calculated).
Uniprot: P10600
RRID: AB_2833435

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(91%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(92%), Dog(100%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
TGFB3 antibody detects endogenous levels of total TGFB3.
RRID:
AB_2833435
Cite Format: Affinity Biosciences Cat# AF0261, RRID:AB_2833435.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ARVD; ARVD1; FLJ16571; LDS5; MGC105479; MGC118722; prepro-transforming growth factor beta-3; RNHF; TGF beta 3; TGF beta3; TGF-beta-3; TGFB 3; Tgfb3; TGFB3_HUMAN; transforming growth factor beta 3; Transforming growth factor beta-3;

Immunogens

Immunogen:
Uniprot:

P10600(TGFB3_HUMAN) >>Visit HPA database.

Gene(ID):
TGFB3(7043)
Description:
TGFB3 Involved in embryogenesis and cell differentiation. Belongs to the TGF-beta family. Homodimer; disulfide-linked. Interacts with ASPN.
Sequence:
MKMHLQRALVVLALLNFATVSLSLSTCTTLDFGHIKKKRVEAIRGQILSKLRLTSPPEPTVMTHVPYQVLALYNSTRELLEEMHGEREEGCTQENTESEYYAKEIHKFDMIQGLAEHNELAVCPKGITSKVFRFNVSSVEKNRTNLFRAEFRVLRVPNPSSKRNEQRIELFQILRPDEHIAKQRYIGGKNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHTFQPNGDILENIHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHHNPHLILMMIPPHRLDNPGQGGQRKKRALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTTHSTVLGLYNTLNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKSCKCS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Bovine
100
Sheep
100
Dog
100
Chicken
100
Rabbit
92
Pig
91
Zebrafish
78
Xenopus
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P10600 As Substrate

Site PTM Type Enzyme
K50 Ubiquitination
K162 Methylation
Y185 Phosphorylation
Q293 Methylation
K299 Acetylation

Research Backgrounds

Function:

Transforming growth factor beta-3 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-3 (TGF-beta-3) chains, which constitute the regulatory and active subunit of TGF-beta-3, respectively.

Required to maintain the Transforming growth factor beta-3 (TGF-beta-3) chain in a latent state during storage in extracellular matrix (By similarity). Associates non-covalently with TGF-beta-3 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-3 (By similarity). Interaction with integrins results in distortion of the Latency-associated peptide chain and subsequent release of the active TGF-beta-3 (By similarity).

Transforming growth factor beta-3: Multifunctional protein that regulates embryogenesis and cell differentiation and is required in various processes such as secondary palate development (By similarity). Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-3 (TGF-beta-3) chains remain non-covalently linked rendering TGF-beta-3 inactive during storage in extracellular matrix (By similarity). At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP that control activation of TGF-beta-3 and maintain it in a latent state during storage in extracellular milieus (By similarity). TGF-beta-3 is released from LAP by integrins: integrin-binding results in distortion of the LAP chain and subsequent release of the active TGF-beta-3 (By similarity). Once activated following release of LAP, TGF-beta-3 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal (By similarity).

PTMs:

Transforming growth factor beta-3 proprotein: The precursor proprotein is cleaved in the Golgi apparatus to form Transforming growth factor beta-3 (TGF-beta-3) and Latency-associated peptide (LAP) chains, which remain non-covalently linked, rendering TGF-beta-3 inactive.

Methylated at Gln-293 by N6AMT1.

Subcellular Location:

Secreted>Extracellular space>Extracellular matrix.

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Interacts with ASPN. Latency-associated peptide: Homodimer; disulfide-linked. Latency-associated peptide: Interacts with Transforming growth factor beta-3 (TGF-beta-3) chain; interaction is non-covalent and maintains (TGF-beta-3) in a latent state (By similarity). Latency-associated peptide: Interacts with LRRC32/GARP; leading to regulate activation of TGF-beta-3 and promote epithelial fusion during palate development (By similarity). Latency-associated peptide: Interacts (via cell attachment site) with integrins, leading to release of the active TGF-beta-3 (By similarity). Transforming growth factor beta-3: Homodimer; disulfide-linked. Transforming growth factor beta-3: Interacts with TGF-beta receptors (TGFBR1 and TGFBR2), leading to signal transduction (By similarity).

Family&Domains:

Belongs to the TGF-beta family.

Research Fields

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Human Diseases > Cardiovascular diseases > Hypertrophic cardiomyopathy (HCM).

· Human Diseases > Cardiovascular diseases > Dilated cardiomyopathy (DCM).

References

1). Exosomes Derived from Epidermal Stem Cells Improve Diabetic Wound Healing. Journal of Investigative Dermatology, 2022 (PubMed: 35181300) [IF=6.5]

Application: WB    Species: Human    Sample:

Supplementary Figure S8. ESCs-Exo treatment of FB in vitro activates TGFb and Akt signaling. (a‒c) Expression levels of TGFb1, SMAD2/3, and quantification. (d‒g) Expression levels of TGFb2, TGFb3, pSMAD2/3 (Thr8), and quantification. (h‒k) Expression levels of Akt and pAkt and quantification. n ¼ 3 biological replicates. Data are represented as mean SD; one-way ANOVA with Fisher’s posthoc test. *P < 0.05 versus control and #P < 0.05 versus FB-Exo. Akt, protein kinase B; ESC-Exo, epidermal stem cellederived exosome; FB, fibroblast; FB-Exo, fibroblast-derived exosome; pAkt, phosphorylated protein kinase B; pSMAD, phosphorylated SMAD.
2). Neochlorogenic acid anchors MCU-based calcium overload for cancer therapy. Food & Function, 2021 (PubMed: 34672304) [IF=6.1]
3). CD4+LAG3+T cells are decreased in SSc-ILD and affect fibroblast mesenchymal transition by TGF-β3. iScience, 2023 (PubMed: 38025770) [IF=5.8]

Application: IF/ICC    Species: Human    Sample:

Figure 2 The proportion of CD4+LAG3+T cells in peripheral blood and its correlation with laboratory indexes Expression of CD4, LAG3, and TGF-β3 in clinical samples. (A) Compared with control group, the proportion of CD4+LAG3+T cells was decreased in SSc patients, and further decreased in complex with ILD. Data are represented as mean ± SD. Statistical significance was analyzed by one-way ANOVA (n = 3), ∗p < 0.05. (B and C) Compared with control group, CD4 and LAG3 were up-regulated and TGFβ3 was down-regulated in lung tissues of SSc-ILD patients. (D) CD4+LAG3+T cell proportion was not significantly correlated with Scl-70 and inflammatory markers CRP and ESR but was significantly negatively correlated with IL-6. (E) Compared with control group, the TGF-β3 content in peripheral blood was decreased in SSc patients, and further decreased in complex with ILD. Data are represented as mean ± SD. Statistical significance was analyzed by one-way ANOVA (n = 5), ∗p < 0.05.
4). Thyrotropin induces atherosclerosis by upregulating large conductance Ca2+-activated K+ channel subunits. Molecular and cellular endocrinology, 2024 (PubMed: 38184154) [IF=4.1]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.